SANOFI-AVENTIS AND REGENERON PHARMACEUTICALS REAFFIRM DEVELOPMENT COMMITMENT

Sanofi-aventis has announced that, following a review of the Vascular Endothelial Growth Factor (VEGF) Trap program, it has reaffirmed its commitment to develop the VEGF Trap in oncology in collaboration with Regeneron Pharmaceuticals. The companies will evaluate the VEGF Trap in a variety of cancer types, both in single-agent studies and in combination with chemotherapy. Sanofi-aventis also announced that Regeneron has earned a $25 million clinical development milestone payment.

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=7205992af26752c6&cat=6dcd932030878143)